Therapeutics News

In recognition of World Glaucoma Week, March 7-13, Justin A. Schweitzer, OD, FAAO, spoke about the number of new options in the optometrist’s toolbox to diagnose and treat glaucoma to both catch the disease early and treat those affected.

Patients treated with Vyzulta for open-angle glaucoma and ocular hypertension had significantly better outcomes compared with most beta-blockers, according to results of a systemic review and network meta-analysis.

NOV03 treatment was found to reduce signs and symptoms of dry eye disease in a phase 2 clinical study.

Metformin use may be associated with a reduced risk for developing age-related macular degeneration, according to study results published in JAMA Ophthalmology.

Use of nucleoside reverse transcriptase inhibitors was associated with a reduced risk for developing dry age-related macular degeneration, according to a study published in Proceedings of the National Academy of Sciences.

About 17.2 million American adults received a diagnosis of dry eye disease, as reported in a 2019 Market Scope report.

Functional vision loss is predictive of retinal nerve fiber layer thinning in patients with glaucoma, according to a study published in Investigative Ophthalmology and Visual Science.

With myopia on the rise, optometrists find themselves on the front lines of the epidemic. Myopia management has gained traction in the U.S. in the past several years and has remained a hot topic in optometry today.

Eyenovia Inc. announced that it submitted a new drug application to the FDA for its fixed combination mydriatic agent, MydCombi.

Prices of branded glaucoma medications increased in the U.S. over the past 7 years, according to a study published in the Journal of Glaucoma.